FBL9 Antibody

Molecular Identity of FBL9

FBL9 (FBXL9, LRRC29) is a member of the F-box protein family, characterized by a leucine-rich repeat (LRR) domain and involvement in the Skp1-Cullin-F-box (SCF) ubiquitin ligase complex. It binds phosphorylated substrates to promote ubiquitination and proteasomal degradation .

Key Features:

• Gene Symbol: LRRC29 (Human)

• Protein Size: ~24 kDa (predicted)

• Domains:

  • F-box domain (substrate recognition)

  • Leucine-rich repeats (protein-protein interactions)

Protein Detection

• Western Blot: Detects endogenous LRRC29 in HEK-293T cell lysates at ~24 kDa .

• Immunohistochemistry: Localizes LRRC29 in formalin-fixed paraffin-embedded (FFPE) human tissues, including the esophagus .

Functional Insights

FBL9 antibodies enable studies on:

• Ubiquitination Pathways: FBL9’s role in substrate recognition for SCF-mediated degradation .

• Cancer Research: LRRC29 expression patterns in tumors (e.g., cervical and pancreatic cancers) .

Validation and Quality Control

• Enhanced Validation: Recombinant protein expression and protein array testing confirm specificity .

• Cross-Reactivity: No observed reactivity with non-target proteins in human samples .

Therapeutic and Diagnostic Potential

While FBL9 antibodies are currently research tools, their utility in drug discovery is emerging:

• Antibody Engineering: Fc-effector function modulation (e.g., L234A/L235A mutations) could enhance therapeutic profiles .

• Biomarker Studies: LRRC29 expression analysis in cancers may inform prognostic strategies .

Market Trends

The global research antibodies market is projected to grow at a 9.2% CAGR (2023–2028), driven by demand for precision tools in oncology and immunology . FBL9 antibodies align with trends in targeted protein degradation research.

Limitations and Future Directions

• Functional Studies: Limited data on FBL9’s physiological substrates.

• Therapeutic Development: Requires structural optimization (e.g., affinity maturation) .